$MLAB

Sullivan John James sold $800K of MLAB

Sullivan John James sold 7,093 shares of MESA LABORATORIES INC /CO/ (MLAB) at $112.80 ($0.80M total) on 2026-08-13.

Original reporting
SEC EDGAR · Sullivan John James
Published Aug 17, 2026, 4:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 4:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MLAB
Neutral
high confidence
Mentioned
$MLAB
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

The newest information is the director’s open-market sale size and price ($112.80/share) disclosed in the filing; it can influence short-term sentiment but does not provide new fundamentals.

02

Market read

Traders may monitor insider selling as a sentiment input, but this specific disclosure lacks any fundamental catalyst in the provided text.

03

What to watch

The text does not state whether the sale was part of a 10b5-1 plan (it says no), nor does it provide context like total compensation, tax events, or prior sale history.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-17, transaction dated 2026-08-13

Background

The article is a SEC Form 4 insider transaction report for MESA LABORATORIES INC /CO/ (MLAB).

Company-level read

Ticker impact

$MLABNeutralHigh confidence
Context

MLAB director Sullivan John James sold 7,093 shares in an open-market transaction worth about $800,090, per a new Form 4 filing.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a routine Form 4 open-market sale by a director, with no 10b5-1 plan indicated and no accompanying operational or guidance change disclosed in the text.

Market effects

No sector-level implications are provided; the disclosure is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or liquidity needs and may not signal reduced confidence, especially without any accompanying negative company news.

Key entities

  • MLAB

    MESA LABORATORIES INC /CO/, issuer of the Form 4 insider sale.

  • Sullivan John James

    Director who sold 7,093 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MLABMedAI 8/10

Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million…

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth The Restructuring Program focuses Clinical Genomics on profitability and adds resources in

$MLABMedAI 8/10

Mesa Laboratories (MLAB) Q1 2027 Earnings Call Transcript

Mesa Laboratories (MLAB) reported Q1 FY2027 revenues of $60.1 million, up 1% year over year, with core organic growth of 0.4%. Adjusted operating income was $15.4 million, up 19.5%, and gross margin rose to 64.9%. Net leverage fell to 1.85x after $8.7 million debt repayment. SDC revenue was $24.5 million, down 3.6% organically.

$MLABMed

Mesa Labs Announces First Quarter Results

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado , August 10, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announc

$MLABHighAI 9/10

Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

Mesa Laboratories (NASDAQ:MLAB) reported 4Q26 revenues up 2.6% to $63.7M and FY26 revenues up 3.4% to $249.1M. Operating income rose 87% to $2.75M in 4Q26 and 13.3% to $18.5M in FY26. Non-GAAP AOI excluding unusual items increased 49.2% (4Q26) and 11.9% (FY26); FY26 free cash flow was $39.6M, used mainly to repay $14.7M debt, reducing net leverage to 2.11.